SOAANZ Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $100
Remove trial restrictions
When do Soaanz patents expire, and when can generic versions of Soaanz launch?
Soaanz is a drug marketed by Sarfe Pharms and is included in one NDA. There is one patent protecting this drug.
This drug has two patent family members in two countries.
The generic ingredient in SOAANZ is torsemide. There are sixteen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the torsemide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Soaanz
A generic version of SOAANZ was approved as torsemide by TEVA on May 14th, 2002.
Summary for SOAANZ
| International Patents: | 2 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 126 |
| Patent Applications: | 4,658 |
| Formulation / Manufacturing: | see details |
| What excipients (inactive ingredients) are in SOAANZ? | SOAANZ excipients list |
| DailyMed Link: | SOAANZ at DailyMed |
Pharmacology for SOAANZ
| Drug Class | Loop Diuretic |
| Physiological Effect | Increased Diuresis at Loop of Henle |
US Patents and Regulatory Information for SOAANZ
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sarfe Pharms | SOAANZ | torsemide | TABLET;ORAL | 213218-001 | Jun 14, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Sarfe Pharms | SOAANZ | torsemide | TABLET;ORAL | 213218-003 | Nov 17, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sarfe Pharms | SOAANZ | torsemide | TABLET;ORAL | 213218-002 | Jun 14, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SOAANZ
See the table below for patents covering SOAANZ around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 3065718 | FORMULATIONS À LIBÉRATION CONTRÔLÉE COMPRENANT DU TORSÉMIDE (CONTROLLED-RELEASE FORMULATIONS COMPRISING TORSEMIDE) | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 2015050570 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
